ctDNA response after pembrolizumab in non-small cell lung cancer: phase 2 adaptive trial results. Anagnostou V, Ho C, Nicholas G, Juergens RA, et al. Nat Med 2023 Oct 9. doi: 10.1038/s41591-023-02598.

Read + Share

Amedeo Smart

Independent Medical Education

Anagnostou V, Ho C, Nicholas G, Juergens RA, et al. ctDNA response after pembrolizumab in non-small cell lung cancer: phase 2 adaptive trial results. Nat Med 2023 Oct 9. doi: 10.1038/s41591-023-02598.
PMID: 37814061